PBAC says no to higher price for blockbuster

Four years after winning a recommendation for Dupixent to treat chronic severe atopic dermatitis in children aged six months to 11 years, but at the same price as for those aged over 12 years, Sanofi returned with a revised proposal for a higher price for the younger cohort and was knocked back.